Deep search
Rewards
Search
Copilot
Images
Videos
Maps
News
Shopping
More
Flights
Travel
Hotels
Real Estate
Notebook
Top stories
Sports
U.S.
2024 Election
Local
World
Science
Technology
Entertainment
Business
More
Politics
Any time
Past hour
Past 24 hours
Past 7 days
Past 30 days
Best match
Most recent
Mylan, Ozempic and Novo Nordisk
Mylan settles patent litigation with Novo Nordisk over generic Ozempic in United States
“Mylan Pharmaceuticals Inc. and Novo Nordisk have reached a settlement of the US patent litigation related to generic Ozempic (Semaglutide),” NATCO said in the filing. The terms of the settlement are confidential, it added.
Mylan and Novo Nordisk settle US generic Ozempic dispute, Natco Pharma poised for market entry
Mylan and Novo Nordisk have reached a confidential settlement over the generic version of Ozempic, with Natco Pharma holding Sole First-to-File (FTF) status for multiple strengths of Ozempic and Wegovy.
Settlement Reached in Ozempic Patent Battle
NATCO Pharma Ltd announced that Mylan Pharmaceuticals Inc has settled a lawsuit with Novo Nordisk in the US concerning the generic version of Ozempic—a medication used for controlling blood sugar and weight loss.
Natco Pharma soars after Mylan settles Ozempic patent dispute
Natco Pharma rose 3.39% to Rs 1400.60 after the company announced a settlement in the U.S. patent litigation for generic Ozempic.
Natco Pharma shares rise 4% on settlement order in US patent case over generic Ozempic
The strong up move was seen in the stock price with the scrip touching the day's high of Rs 1,408.70 per share on the NSE, rising 4 percent.
Natco Pharma settles US patent case over generic Ozempic
According to data from the BSE index, the stock has achieved multibagger gains over the last two years, climbing 122.04%.
Natco Pharma partner Mylan settles patent litigation with Novo Nordisk over generic Ozempic in US
Hyderabad: NATCO Pharma Limited has announced that its partner Mylan Pharmaceuticals Inc. and Novo Nordisk have reached a settlement of the U.S. patent litigation related to generic
Natco Pharma shares gain after settlement in US patent litigation on generic Ozempic
Mylan Pharmaceuticals Inc and Novo Nordisk, the original patent holder for Ozempic, have reached a settlement in the US patent litigation concerning the drug, Natco Pharma informed the stock exchanges in a filing.
Mylan Settles Patent Suit with Novo Nordisk over Generic Ozempic
Mylan Pharmaceuticals Inc. and Novo Nordisk have reached a settlement in the US over a patent infringement lawsuit regarding generic Ozempic, a drug used for blood sugar and weight loss.
4h
Here's why Natco Pharma share price gained over 4% on October 7; details
Natco Pharma share rose after the company announced that Mylan Pharmaceuticals Inc & Novo Nordisk have reached a settlement ...
5h
on MSN
Natco Pharma shares jump 4% amid weak broader markets; here' why
Shares of Natco Pharma Ltd surged nearly 4.35 per cent to Rs 1,413.45 on Monday, commanding a total market capitalization ...
5d
Ex-Mylan executive gets prison time in $8M insider trading scheme
A former Mylan executive who pleaded guilty to insider trading in the pharmaceutical company’s stock will serve two years in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Trending now
Madonna's brother dies
Fans throw objects on field
Canyoneering fall death
Father-son duo make history
US, UK climbers rescued
FAA authorizes Oct 7 flight
Bear w/ 3 cubs attacks man
Novelist Robert Coover dies
ISR October 7 anniversary
Synagogue threats arrest
More troops to aid recovery
2 boys arrested for assault
Trump's Wisconsin rally
Ex-Lions quarterback dies
Man sets self on fire in DC
Antisemitic incidents surge
Wins China Open final
Warns of potential threats
Heavy strikes shake Beirut
Sixth Player of the Year
Won’t renew CHNV parole
To resume talks with union
US $157M aid for Lebanon
Names 21 new cardinals
Catches fire while landing
US, SK troop-funding deal
Glover cancels tour dates
Bans pagers, walkie-talkies
Man charged for threats
Pereira defeats Rountree
Tucker faces defamation suit
Related topics
Ozempic
United States
Novo Nordisk
Natco Pharma
Feedback